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ABSTRACT One of the most extensively studied receptor tyrosine kinases is EGFR/ErbB1. Although our knowledge of the role
of the extracellular domains and ligands in ErbB1 activation has increased dramatically based on solved domain structures, the
exact mechanism of signal transduction across the membrane remains unknown. The transmembrane domains are expected to
play an important role in the dimerization process, but the contribution of ErbB1 TM domain to dimer stability is not known, with
published results contradicting one another. We address this controversy by showing that ErbB1 TM domain dimerizes in lipid
bilayers and by calculating its contribution to stability as2.5 kcal/mol. The stability calculations use two different methods based
on Fo¨rster resonance energy transfer, which give the same result. The ErbB1 TM domain contribution to stability exceeds the
change in receptor tyrosine kinases dimerization propensities that can convert normal signaling processes into pathogenic
processes, and is thus likely important for biological function.Receptor tyrosinekinases (RTKs) are the second largest family
of membrane receptors. They are single-pass membrane
proteins consisting of an extracellular ligand-binding domain,
a transmembrane domain (TM), and a cytosolic catalytic
domain (1). Unlike G-protein coupled receptors, a single
monomeric RTK cannot effectively transduce biochemical
signals across the plasmamembrane. Thus, lateral interactions
between RTKs are critical for their function (2,3). It is well
established that the first step in RTK signaling is the formation
of an RTK dimer in the plasmamembrane, a process that leads
to the activation of the dimerized receptors. The dimerization
event regulates RTK activity by controlling the distribution
between inactive monomers and active dimers, and ultimately
exerts control over various cellular processes, such as cell
proliferation, differentiation, survival, and migration. Defects
in dimerization lead to disease (4), and inhibitors of the dimer-
ization events are already recognized as possible therapeutics
with applications in the clinic, and are in trials or are approved
(such as Vectibix (Amgen, Thousand Oaks, CA) and Erbitux
(ImClone Systems, Branchburg, NJ) for ErbB1 and Pertuzu-
mab (Genentech, San Francisco, CA) for ErbB2 (5)).
Crystal structures of isolated extracellular (ligand binding)
domains have been solved over the past decade, and they
have provided new insights into ligand binding and dimeriza-
tion (6). For instance, the high-resolution structures of ErbB
and FGFR ligand binding domains have shown that for these
receptors, the ligands control the equilibrium between the
dimerization-competent and incompetent states of the extracel-
lular domains, by stabilizing the competent state (7–11). Thus,
the successes in structure determination have lead to a dramatic
increase in themechanistic understanding of the initial steps of
RTK dimerization. However, the exact mechanism of signal
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0006-3495/09/06/4622/9 $2.00transduction across the membrane (i.e., the mechanism
through which the interactions between the extracellular
domains lead to phosphorylation within the catalytic domains)
remains unknown. Because crystal structures of full-length
receptors are not available, the question of how the information
is communicated from the ligand binding domains to the cata-
lytic domains has been addressed primarily in biochemical
studies. In one such study, Bell et al. (12) observed that the
rotation of the TMdimer interface leads to periodic oscillations
in kinase activity. Furthermore, inserting residues in the
C-terminal TM flanking region, which causes the kinase
domain to rotate with respect to the TM domain, restores the
kinase activity of the inactive receptors. These experiments
show that 1), the optimal activation of an RTK occurs only
for a specific TM dimer interface, and 2), the RTK TM dimer
interface contains the critical structural information that posi-
tions the catalytic domains in such a way that they can phos-
phorylate each other. Consistent with this view, it has been
proposed that at least someTMdomains have twodimerization
motifs, corresponding to active and inactive dimer structures
(13,14). Within this view of RTK activation, the TM domains
play an important structural role during the dimerization
events, and are thus critical for the dimerization process and
for RTK activation (15). In addition, the TM domains may
be contributing to the stability of the full-length RTK dimers
(16). In particular, if the TM domains form sequence-specific
dimers, the RTK dimer interface would include contacts
between the TM domains, and these contacts will contribute
to dimer stabilization. A question remains, however, as to
how large the TM domain contribution to dimer stability is.
One of the most extensively studied receptors is EGFR/
ErbB. In one study, aimed at elucidating the relative contribu-
tions of the extracellular domain and the TM domain for this
receptor, Tanner and Kyte showed that the extracellular
EGFR domains dimerize strongly only in the presence of the
TM domains (17). They estimated that the dissociation
constant of the extracellular domains, when attached to the
doi: 10.1016/j.bpj.2009.03.004
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the dissociation constant of the isolated extracellular domains.
The dimerization of ErbB1 TM domains has been further
investigated using the genetic TOXCAT or ToxR assays
(13,14). These assays couple transmembrane segment asso-
ciation with the expression of chloramphenicol acetyltrans-
ferase or b-galactosidase, which is measured. These studies
have shown that the TM domains of ErbB1 dimerize in
bacterial membranes, consistent with the results of Tanner
and Kyte (17). However, the TOXCAT/ToxR assays do
not readily yield information about the oligomer size and
the free energy of dimerization, a thermodynamic character-
istic that allows to predict the occurrence of active dimeric
species at any concentration (expression level), and to
compare the contribution of the different domains in the
dimerization process.
Techniques that can provide such quantitative thermody-
namic data are Fo¨rster resonance energy transfer (FRET)
and analytical ultracentrifugation, the latter being applicable
only for detergent environments. Interactions between
ErbB1 TM domains were detected in the detergent dimethyl-
dodecylamine N-oxide using FRET (18). Surprisingly, no
interactions were observed between ErbB1 TM domains in
C5E8 detergent using analytical ultracentrifugation (19), in
contradiction with the results of Tanner and Kyte (17), and
with the TOXCAT/ToxR results. This contradiction raises
two possibilities. The first is that the results of Tanner and
Kyte (17) and the bacterial assay results do not register
sequence-specific dimerization, but excluded volume or
proximity effects, and the ErbB1 TM domains do not really
interact (19). The second is that the TM domains dimerize in
the native bilayer environment, but the interactions are abol-
ished in detergent micelles, suggesting that detergents are not
an appropriate system for studies of RTK TM domains, as
proposed by Engelman and colleagues (20).
One way to resolve this controversy is to characterize the
thermodynamicsofErbB1dimerization in lipid bilayers.Quite
remarkably, despite all the workwith ErbB TMdomains, such
a measurement remains lacking for ErbB1. We present exper-
imental results showing that ErbB1 TM domain dimerizes in
a lipid bilayer environment. The free energy of dimerization
is calculated using two different FRET-based methods, which
give very similar results. These results reinforce the idea that
RTK TM domains are not passive anchors during the dimer-
ization process, and their interactions contribute a few kcal/
mol to the overall stability of the RTK dimers. We show
sequence-specific dimerization of ErbB1 TM domain in lipid
bilayers, consistent with the proposed important structural
role for RTK TM domains in signal transduction.
MATERIALS AND METHODS
Materials
1-Palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) and 1,2-di-
lauroyl-sn-glycero-3-phosphocholine (DLPC) were purchased from AvantiPolar Lipids (Alabaster, AL). The ErbB1 TM domain, amino acid sequence
KKKSIATGVVGALLLLLVVALGIGLFMKKK, was synthesized using
solid phase peptide synthesis, and labeled with the FRET pair of fluorescein
(Fl) and rhodamine (Rhod). The labeled and unlabeled peptides were puri-
fied (>98% homogeneity) by reverse phase HPLC on a C4 column using
a linear gradient of 30%–80% acetonitrile in water containing 0.1% TFA,
for 40 min. The peptides were subjected to amino acid analysis and mass
spectrometry to confirm their composition and mass.
SDS-PAGE
Between4–8nmolof thepeptidewere subjected toSDS-PAGEusingNuPAGE
NovexTris-AcetateMiniGels (Invitrogen, Carlsbad,CA), following themanu-
facturer’s protocol. The peptides were visualized with Coomassie blue.
Preparation of vesicles for circular dichroism and FRET
measurements
Vesicles were prepared as described previously (21–23). Briefly, donor-
labeled peptides, acceptor-labeled peptides, unlabeled peptides (as appro-
priate) and lipids were first mixed in TFE/chloroform, the organic solvents
were removed, and the protein/lipid mixture was redissolved in 10 mM
phosphate buffer, 500 mM NaCl, pH 7. Samples were then freeze-thawed
several times, which substantially decreased the turbidity of the samples.
We have shown that both circular dichroism (CD) and FRET spectra can
be measured in such vesicles (23).
CD
The secondary structure of ErbB1 TM domain was recorded in TFE, as well
as in POPC and DLPC vesicles in 10 mM phosphate with 500 mM NaCl, at
pH ¼ 7. The vesicles were prepared as described above. The CD spectra
were collected using a Jasco spectropolarimeter (Oklahoma City, OK).
Oriented CD
Oriented CD measurements were carried out in DLPC multilayers as re-
ported previously (24–26). Dropwise, a solution of peptides and lipids in
TFE/chloroform was deposited on a quartz slide and the solvent was
removed under a stream of nitrogen to form a multilamellar sample contain-
ing the peptides. The quartz slide with the deposited multilamellar sample
was placed in a custom designed chamber, and hydrated through the vapor
phase as described (27,28). CD spectra were recorded while the sample was
rotated around the beam axis in increments of 45. The eight recorded
spectra were averaged and corrected for lipid background.
FRET
FRET experiments in DLPC vesicles were carried out in a Fluorolog fluorom-
eter (Jobin Yvon, Edison, NJ) using Fl and Rhod as a donor/acceptor pair. The
Fo¨rster radius, R0, for this pair is 56 A˚ (29). FRET was measured in liposomes
containing donor- and acceptor-labeled peptides, by fixing the excitationwave-
length at 439 nm, and collecting emission spectra from 455 nm to 700 nm. The
FRET efficiency, E, was calculated from the decrease in donor fluorescence at
519 nm, while using the EmEx-FRET method to eliminate uncertainties in
peptide concentrations due to aliquoting (30). The measured FRET efficiency
was used to calculate the free energy of dimerization as shown below.
Free energy calculations
The association constant K describing the monomer-dimer equilibrium in
liposomes depends only on the protein/lipid ratio (23) and is given by:
K ¼ ½D½M2; (1)
where [D] is the dimer molar concentration in the liposomes (dimers per
lipid) and [M] is the monomer molar concentration in the liposomes (mono-
mers per lipid).Biophysical Journal 96(11) 4622–4630
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peptide/lipid ratio. In these experiments, the measured FRET efficiency has
two contributions: one due to sequence-specific dimerization and one due to
random colocalization (proximity) of donors and acceptors. The proximity
contribution, Eproximity, is modeled computationally as described in (21,23)
and subtracted from the measured FRET efficiency E to obtain the contribu-
tion due to sequence-specific dimerization.
Edimer ¼ E Eproximity: (2)
On the other hand,
Edimer ¼ fD  xa; (3)
where fD ¼ 2½D½T is the dimeric fraction, xa ¼
½a
½d þ ½a is the acceptor
fraction, and T is the total peptide concentration, ½T ¼ ½d þ½a . Here [d]
and [a] denote the donor and acceptor concentration, respectively.
Thus, the dimer concentration can be calculated as:
½D ¼ Edimer  ½T
2xa
: (4)
The monomer concentration is given by ½M ¼ ½T 2½D , and the equilib-
rium constant K is determined using Eq. 1.
Finally, the free energy of dimerization is calculated as:
DG ¼ RTlnK: (5)
The major shortcoming of the above method is the fact that FRET due to
sequence-specific dimerization is obtained by subtracting a calculated contri-
bution from the experimentally measured FRET efficiency. Whereas multiple
lines of evidence have shown that the proximity contribution model is correct
(21,29,31), a second independentmethod to characterize the dimerization ener-
getics that does not depend on the exact value of Eproximity is highly desirable.
Occurrence of sequence-specific dimerization can be shown directly by
measuring the change in the FRET efficiency upon the addition of unlabeled
peptides (32). It has been shown that if dimerization occurs, the addition of
unlabeled peptides to donor- and acceptor-labeled dimers will decrease the
FRET efficiency (21,32). This control experiment has shown that glyco-
phorin A and FGFR3 form sequence-specific dimers in SDS and in POPC
vesicles, respectively (21,32). We show that this method can be extended
to yield equilibrium constants, independently from the calculations
described by Eqs. 2–4 above. The advantage of this new alternative method
is that Eproximity does not change in the presence of the unlabeled peptide
(because it depends only on the acceptor concentration). Thus, the measured
decrease in the FRET efficiency is only due to changes in the sequence-
specific FRET, Edimer. The change in the measured FRET efficiency, DE,
from E1 to E2 after the addition of unlabeled peptide is:
DE ¼ E1  E2
¼ Edimer;1 þ Eproximity;1 Edimer;2 þ Eproximity;2
¼ Edimer;1  Edimer;2
¼ fD;1  xa;1  fD;2  xa;2:
(6)
Furthermore,
K ¼ ½D½M2 ¼
½D
ð½T  2½DÞ2: (7)
From Eq. 7, we obtain the following quadratic equation for [D]:
Kð½T  2½DÞ2¼ ½D:
The solution for this equation is:
½D ¼ 4K½T þ 1 
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
8K½T þ 1p
8K
;
Biophysical Journal 96(11) 4622–4630and the dimetic fraction is:
fD ¼ 2½D½T ¼ 1 þ
1
4K½T 
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
8K½T þ 1p
4K½T :
Because fD % 1,
fD ¼ 1 þ 1
4K½T 
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
8K½T þ 1p
4K½T :
By substituting fD into Eq. 6, we obtain
DE ¼
 
1 þ 1
4K½T1

ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
8K½T1þ 1
p
4K½T1
!
 ½a1½a1þ ½d1

 
1 þ 1
4K½T2

ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
8K½T2þ 1
p
4K½T2
!
 ½a2½a2þ ½d2þ ½u
: (8)
In Eq. 8, ½T1 ¼ ½d1 þ ½a1, and ½T2 ¼ ½d2 þ ½a2 þ ½u, where [d] and [a]
are the donor and acceptor concentrations defined above, and [u] is the
concentration of unlabeled peptide.
The only unknown in Eq. 8 is the equilibrium constant K, such that K can
be easily determined. The free energy of dimerization is calculated according
to Eq. 5.
A problem may arise, however, if the interactions between the TM
domains are weak (such as the weak interactions measured for two other
RTK TM domains, FGFR3 (29) and EphA1 (33)). Then DE would be small,
and thus special precautions should be taken to reduce random errors. We
thus used the following protocol for sample preparation. Lipids in chloro-
form were mixed with donor-labeled and acceptor-labeled peptides in
TFE. Then, the sample was slit into two ‘‘twin’’ samples, and unlabeled
peptides were added to only one of them. The organic solvents in the
samples were removed and the samples were hydrated to produce liposomes.
This procedure ensured that the labeled peptide and lipid concentrations
were identical, and most importantly, the donor/acceptor molar ratio was
exactly the same in both samples. Experimental uncertainties are limited
to possible variations in the reconstitution of the peptides in the vesicles.
Thus, the changes of the ratio of the sensitized acceptor emission Isen to
the emission of the donor in the presence of the acceptor Ida upon the addi-
tion of the unlabeled peptides was used to determine DE.
As discussed in detail in Merzlyakov et al. (30), the sensitized acceptor
emission Isen is equal to the decrease in donor emission in the presence of
the acceptor DId for the Fl/Rhod pair, more precisely Isen/DId ¼ 1.00 
0.05 (30). Therefore:
E ¼ DId
Id
¼ DId
Ida þ DId ¼
Isen
Ida þ Isen ¼
Isen=Ida
Isen=Ida þ 1: (9)
The decrease in the FRET efficiency in the presence of unlabeled peptides
was calculated as:
DE ¼

Isen=Ida
Isen=Ida þ 1

no unlabeled


Isen=Ida
Isen=Ida þ 1

with unlabeled
:
(10)
RESULTS
SDS-PAGE
To probe the dimerization propensities of ErbB1 TM
domains, we first subjected the TM domains to SDS-PAGE.
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ing to amolecular weight between the expectedweights of the
monomer (~3000) and the dimer (~6000). Because TM
domains are known to sometimes run anomalously on a gel
(34), it is not clear if this single band corresponds to mono-
meric or dimeric species. The observation of a single band
is consistent with previous studies of a construct of ErbB1
TMdomain linked to a soluble protein, which runs as amono-
mer (19). Thus, although our data cannot prove it, it can be
argued that the band in Fig. 1 is monomeric.
FIGURE 1 ErbB1 TM domain runs as a single band on an SDS-PAGE
gel. In this experiment 8 nmol of the peptide were dissolved in 1 NuPAGE
LDS sample buffer and heated at 70C for 10 min before loading onto
NuPAGE Novex Tris-Acetate Mini Gel. The gel was run at 150 V for 1 h.
The peptide was visualized by staining with Coomassie brilliant blue.The ErbB1 dimerization propensity in SDS can be
compared to the propensity of other characterized RTK
TM domains, such as FGFR3 TM domain and its pathogenic
mutants (22,29,35), which exhibit both monomeric and
dimeric bands on SDS gels. Thus, ErbB1 TM domain seems
to have a lower dimerization propensity than FGFR3 TM
domain in SDS.
Secondary structure of ErbB1 TM domain
The secondary structure of ErbB1 TM domains in different
hydrophobic environments was characterized using CD.
Fig. 2 A shows the CD spectrum in TFE, which is consistent
with a helical structure, as is the spectrum in SDS (not
shown). Next, we investigated the secondary structure in
POPC vesicles. To our surprise, a single minimum was
observed at ~220 nm (Fig. 2 B), which is characteristic of
b-sheets, rather than a-helices. We hypothesized that the
reason for this observation is that the ErbB1 TM helix with
its flanking lysines may be too short to span the POPC
bilayer. We thus measured the secondary structure of
ErbB1 TM domain in thinner bilayers made of DLPC,
having only 12 carbon acyl chains. As seen in Fig. 2 C,
the CD signal in DLPC (solid line) seems consistent with
a-helix formation, as evidenced by the presence of
a minimum around 208 nm. The quality of this CD signal,
however, is rather poor because of the high turbidity of the
liposomal solutions.
Previous thorough investigations of the suitability of
various liposomal systems for FRET studies have shown
that both multilamellar vesicles that have been subjected to
several freeze-thaw cycles and extruded large unilamellar
vesicles are appropriate for FRET studies of TM helixA
B
C
D
FIGURE 2 (A) CD spectrum of ErbB1 TM domain in
TFE. (B) CD spectrum of ErbB1 TM domain in POPC
vesicles. The spectrum suggests b-sheet secondary struc-
ture. (C) CD spectrum of ErbB1 TM domain in DLPC vesi-
cles (solid line). Although the turbidity of the liposomal
solution is high, this spectrum is indicative of a-helical
secondary structure. The CD spectra after sonication
(dotted line) and after the addition of Triton-X (2 detergent
molecules per 100 lipids, dashed line) confirm that the
secondary structure is a-helical (see text). (D) Oriented
CD spectrum of ErbB1 TM domain in oriented DLPC
multilayers. The spectrum is consistent with transmem-
brane orientation.Biophysical Journal 96(11) 4622–4630
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systems, however, show very high turbidity that obscures the
CD signal. Thus, to convince ourselves that the CD signal in
Fig. 2 C (solid line) is indeed helical, we sonicated the lipo-
somes and recorded the CD signal, which is shown with the
dotted line in Fig. 2 C. We also added small amount of
Triton-X (2 detergent molecules per 100 lipids). These two
procedures reduced the turbidity and allowed us to record
CD spectra of better quality, showing minima around 208
and 222 consistent with a-helical secondary structure. We
thus concluded that DLPC, but not POPC, is an appropriate
bilayer system for studies of ErbB1 dimerization.
Next we investigated if the helix is transmembrane in
DLPC using oriented circular dichroism (OCD). TM helices
exhibit characteristic OCD spectra with a single minimum
around 220–230 nm and a maximum around 200 nm. In
contrast, helices that are parallel to the membrane plane
exhibit a much stronger OCD signal with minima at 208
and 222 nm (25,26). The samples used in the OCD experi-
ments were DLPC multilayers containing 5 mol % ErbB1
TM domain, deposited on a quartz slide. The experimental
OCD spectrum is shown in Fig. 2 D. The shape of the spec-
trum, with a single minimum around 230 nm, indicates that
the ErbB1 TM domain is perpendicular to the DLPC bilayer
normal.
In summary, CD and OCD measurements show that the
ErbB1 peptide is helical and transmembrane in DLPC bila-
yers.
FRET and free energy calculations
For the FRET experiments, the ErbB1 TM domain was
labeled with the FRET pair of Fl/Rhod. The labeled peptides
were purified by HPLC, such that labeling yield was 100%.
The FRET efficiencies for a series of samples containing Fl-
and Rhod-labeled ErbB1 TM domains were measured as
described in Materials and Methods. Fig. 3 shows typical
emission spectra of liposomes containing the donor (Fl)
only (dashed line) and liposomes containing the same
concentration of donor in the presence of the acceptor (Fl
and Rhod, solid line). In Fig. 3, FRET is obvious from the
decrease in donor fluorescence and the appearance of sensi-
tized acceptor fluorescence. FRET efficiency is calculated
as E ¼ DId=Id, where DId is the change in donor emission
at 519 nm, and Id is the donor emission in the absence of
the acceptor at 519 nm.
First, FRET was measured for a constant peptide/lipid
ratio, but varying donor/acceptor ratio. The linear depen-
dence of the energy transfer on the acceptor mole ratio,
shown in Fig. 4, is indicative of dimer formation (23,36–
38). Therefore, ErbB1 TM domain exists in a monomer-
dimer equilibrium and does not form higher order aggre-
gates.
Next, FRET was measured for a constant donor/acceptor
ratio, but varying peptide/lipid ratio. Fig. 5 shows the totalBiophysical Journal 96(11) 4622–4630measured FRET efficiency E as a function of acceptor
concentration (squares). The FRET efficiency that arises
due to random proximity effects was modeled according to
the analysis of Wolber and Hudson (39), and is shown
with the dotted line for comparison. To calculate the FRET
efficiency due to sequence-specific dimerization, Edimer, the
predicted FRET efficiency due to proximity was subtracted
from the measured FRET signal (23). The equilibrium
constant describing the dimerization process was calculated
FIGURE 3 Fluorescence spectra of Fl- and Rhod-labeled peptide
mixtures in liposomes. The spectra shown are for DLPC vesicles with
0.2 mol % Fl-labeled ErbB1 TM domain (dotted line) and for DLPC vesicles
with 0.2 mol % Fl-labeled and 0.2 mol % Rhod-labeled ErbB1 TM domain
(solid line) The excitation was fixed at 439 nm, such that only Fl was directly
excited. The emission was scanned from 455 to 700 nm. FRET efficiency is
calculated from the decrease of Fl emission in the presence of Rhod at
519 nm.
FIGURE 4 Measured FRET efficiency in DLPC vesicles as a function of
acceptor mole ratio. The peptide/lipid ratio was kept constant at 1:500,
whereas the ratio of donor-labeled/acceptor-labeled peptides was varied.
The linear dependence of the energy transfer on the acceptor mole ratio is
indicative of the formation of dimers and shows that there are no higher
order aggregates.
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TM domain, DG, given by Eq. 5, was calculated as 2.5 
0.1 kcal/mol (Table 1).
As discussed in Materials and Methods, the major short-
coming of the above method is that the proximity contribu-
tion is predicted rather than measured. In particular, it
depends on the value of the Fo¨rster’s radius, R0, and the
predictions carry a certain degree of uncertainty (23). This
uncertainly impacts the calculated values of the equilibrium
constants and dimerization free energies, particularly for
weakly dimerizing helices such as ErbB1. Previously, we
have presented various arguments that the predicted prox-
imity contribution is correct (21,29) and we have verified it
using lifetime measurements (31). Nevertheless, in this study
we developed and used a second independent method to
characterize the dimerization energetics. In particular, we
analyzed the decrease in FRET efficiency in the presence
of unlabeled peptides. This experiment has been used previ-
ously to show sequence-specific dimerization (21,32), and
now we show that this method can yield dimerization free
energies.
FIGURE 5 Measured FRET efficiencies for an equimolar mixture of Fl-
and Rhod-labeled peptides in DLPC vesicles (solid symbols), as a function
of Rhod (acceptor) concentration. Whereas the donor/acceptor ratio was
held constant, the peptide/lipid concentration was varied. Also shown is the
prediction for the proximity contribution to the FRET efficiency. For a quan-
titative description of dimerization, themeasuredFRETefficiency is corrected
for this contribution. The free energies of sequence-specific dimerization are
calculated using Eqs. 2–5 and are shown in Table 1.
TABLE 1 Calculations of the dimerization free energy of ErbB1
TM domain, DG, based on Eqs. 2–5 and the FRET efﬁciency
measurements shown in Fig. 5
Protein/lipid ratio (%) DG (kcal/mol)
0.05 2.2
0.1 2.6
0.2 2.5
0.3 2.5
0.4 2.6
Average 2.5  0.1Fig. 5 compares fluorescence spectra of Fl- and Rhod-
labeled ErbB1 peptides in liposomes without and with unla-
beled peptides. The unlabeled peptide is not expected to have
an effect on the FRET signal if the FRET signal is solely due
to random proximity of donors and acceptors. A decrease in
FRET, however, is the hallmark of sequence specific dimer-
ization (32), and it reflects the substitution of donors and
acceptors in donor-acceptor dimers with unlabeled peptides.
In Fig. 6 we see a decrease in the FRET efficiency in the
presence of the unlabeled peptide, which seems rather
modest. Such a modest effect is expected because the
decrease is only in the portion of the measured FRET that
is due to sequence specific dimerization. Although this
modest decrease requires very careful measurements, it
should be noted that because Eproximity has no effect on the
measured change in the FRET efficiency, this method yields
the equilibrium constant K without the explicit knowledge of
Eproximity (see Eq. 8). Equations 5 and 8 were used to calcu-
late K and DG for three different samples containing 0.1 mol
% Fl, 0.1 mol % Rhod, and 0.3 mol % unlabeled peptide.
In three different vials, aliquots of lipids in chloroform, as
well as donor-labeled and acceptor-labeled peptides in TFE
were mixed. Then, the sample in each of the vials was slit
into two ‘‘twin’’ samples, and unlabeled peptides were
added to only one of them. Thus, the labeled peptide and
lipid concentrations were identical within each twin set. A
total of six samples, or three twin sets were examined, and
three values for DG were calculated, one for each twin set,
from the change in FRET according to Eq. 10. The results
are shown in Table 2 and the average is DG ¼ 2.4 
0.4 kcal/mol. The comparison of the values in Tables 1
FIGURE 6 Fluorescence spectra of 0.1 mol % Fl-labeled and 0.1 mol %
Rhod-labeled ErbB1 TM domain in DLPC vesicles (dashed line). The solid
line is the FRET spectrum in the presence of 0.3 mol % unlabeled peptide.
Thus, the FRET efficiency decreases in the presence of the unlabeled
peptide. The free energy of dimerization is calculated from this decrease
using Eqs. 6–10. Three different samples were prepared as described in
the text, and the results for DG are shown in Table 2. The dotted line is
the emission of Fl-labeled ErbB1 in the absence of Rhod-labeled peptides
(i.e., the ‘‘no-FRET’’ control).Biophysical Journal 96(11) 4622–4630
4628 Chen et al.and 2 shows that the two methods yield very similar
results.
DISCUSSION
In this study, we assessed the dimerization propensity of
ErbB1 TM domain in DLPC bilayers, and we calculated
its dimerization free energy. This study addressed a contro-
versy in the literature about the role of ErbB1 TM domains
in the dimerization and activation of the full-length ErbB1
receptor. We showed that sequence-specific interactions
between ErbB1 TM domains do occur in DLPC bilayers,
and the free energy of dimerization is 2.5 kcal/mol. These
results were obtained using FRET, and are based on two
independent FRET-based calculations.
Measurements of TM helix dimerization based
on FRET
As shown previously (23), FRET can yield information
about TM helix dimerization in a lipid bilayer environment.
FRET involves the nonradiative transfer of energy from the
excited state of a donor to an acceptor, both coupled to the
TM domains. If a donor-labeled peptide and an acceptor-
labeled peptide dimerize, the donor and the acceptor will
be brought in close contact in the dimer, such that FRET
will occur. However, FRET can also arise due to proximity
effects, i.e., random colocalization of the donor-labeled
and the acceptor-labeled peptides. Therefore, the measured
FRET efficiency E has two contributions, one due to
sequence-specific FRET, Edimer, and one due to proximity,
Eproximity.
In this study, we used two methods based on FRET to
calculate the dimerization free energy of ErbB1 TM domain.
First, we measured the FRET efficiency for a series of lipo-
somal samples containing donor- and acceptor-labeled
ErbB1 TM, at different peptide/lipid ratios. The modeled
FRET efficiency due to the proximity effect (Eproximity) was
subtracted from the total efficiency (E) to obtain the FRET
efficiency due to sequence specific dimerization (Edimer).
Knowledge of Edimer allowed us to calculate the dimerization
free energy, as described previously (23,35,40). The value is
2.5  0.1 kcal/mol.
TABLE 2 Calculations of the dimerization free energy of ErbB1
TM domain,DG, via dilution with unlabeled peptides, using Eqs.
6–10
Isen/Idano
unlabeled peptide
Isen/Idawith
unlabeled peptide DE DG (kcal/mol)
1 0.346 0.262 0.049 2.9
2 0.367 0.348 0.010 2.0
3 0.347 0.314 0.019 2.3
Average 2.4  0.5
Calculations are based on FRET spectra for 0.1% Fl-labeled and 0.1% Rhod-
labeled peptides in the presence and absence of 0.3% unlabeled peptides
(Fig. 6).Biophysical Journal 96(11) 4622–4630In this study, we also introduced a new method that is
based on the fact that if sequence-specific dimerization
occurs, the addition of unlabeled peptides to the vesicles con-
taining donor- and acceptor-labeled peptides will decrease
the measured FRET efficiency. This decrease is due to the
formation of dimers between the unlabeled peptides and
the donor- or acceptor-labeled peptides. The dimerization
free energy was calculated from the measured decrease in
the FRET efficiency as 2.4  0.4 kcal/mol. Most impor-
tantly, this calculation did not require the explicit knowledge
of the FRET efficiency that arises due to the random coloc-
alization of donors and acceptors. The two methods give
similar results, and we expect that both methods will have
broad use in studies of TM helix dimerization in lipid envi-
ronments.
Dimerization of RTK TM domains in lipid bilayers
and in detergents
SDS-PAGE is a popular technique to asses whether TM
domains have propensity for self-association. In this study,
we observe that ErbB1 TM domain runs as a single band
on a SDS gel, as reported previously (19). In DLPC bilayers,
however, ErbB1 TM domains form dimers, and the free
energy of dimerization in DLPC is2.5 kcal/mol. This value
is similar to the dimerization propensity of FGFR3 TM
domain in POPC, 2.8  0.1 kcal/mol.
One unexpected finding of this study is that although the
strength of the interactions for ErbB1 and FGFR3 TM
domains in lipid bilayers seems similar, ErbB1 runs as
a single band on an SDS gel (most probably a monomer),
whereas FGFR3 monomers and dimers coexist in SDS
(21,22). These findings suggest that there is not always
a strong correlation between TM helix dimerization behavior
in detergents and in bilayers. This result has an important
implication, because SDS-PAGE is often used for an initial
assessment of interactions between TM helices.
RTK TM domains and signal transduction
We measured the dimerization free energy of ErbB1 TM
domain in DLPC bilayers as 2.5 kcal/mol. A major finding
of this study is that the strength of ErbB1 interactions is very
similar to the measured dimerization strengths for two other
RTK TM domains (FGFR3 (29) and EphA1 (33)). Thus, the
interactions within these three RTK TM domain homodimers
are rather weak, and in particular much weaker than the inter-
actions within the well characterized stable glycophorin A
dimer. This finding is not surprising because weak dimeriza-
tion in RTK signaling should allow for a tight control over
the monomer/dimer equilibrium (16). We find it remarkable,
however, that the TM domains of ErbB1, FGFR3, and
EphA1 exhibit very similar dimerization energetics, despite
being members of three different RTK families. It is not
known whether the dimerization propensities of all 59
RTK TM domains are similar, or whether there are variations
Erbb1 Transmembrane Domain Dimerization 4629in the strength of their interactions. In one study (18), in the
detergent dimethyldodecylamine N-oxide, a range of interac-
tion strengths were observed for the TM domains of the ErbB
family of receptors. A question remains whether such hier-
archy exists in lipid bilayers and in cellular membranes.
One of the open questions in RTK signaling pertains to the
relative contribution of the TM domain to full-length RTK
dimer stability. This question is difficult to answer because
association between TM domains is probed in 2D membrane
systems, whereas the interactions between isolated soluble
extracellular domains have been characterized in 3D only
(i.e., in aqueous solution) (41). Thus, the measurements for
the extracellular and TM domains are difficult to compare.
However, we have shown previously that modest changes
in receptor dimerization propensities, of the order of ~
1 kcal/mol, may be enough to cause receptor overactivation,
likely because the signals are amplified downstream in the
signaling cascades (16,42). In this respect, it seems that the
2.5 to 3 kcal/mol that the TM domains are contributing to
RTK dimer stability is important for their biological functions.
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